ArticleRespirology case reports2025
Allergic Bronchopulmonary Mycosis Caused by
Article in Respirology case reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Allergic bronchopulmonary mycosis caused byIDCases · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Allergic bronchopulmonary mycosis (ABPM) is a complication of bronchial asthma (BA) and can lead to lung damage and respiratory failure. The standard treatment for ABPM is steroid therapy. Nonetheless, this treatment increases the risk of infections and osteoporosis. Alternative therapies include immunomodulatory biologics and mucus plug removal by bronchoscopy. This report describes a case of a 70-year-old man diagnosed with BA in 2014 and treated with inhaled corticosteroids/long-acting beta-agonists, which were later discontinued for unknown reasons. He was presented to our department with a BA attack, including wheezing and desaturation. Computed tomography and laboratory examinations suggested ABPM; the patient underwent mucus plug removal. The final diagnosis was ABPM, and steroids and itraconazole were initiated. However, BA symptoms did not improve, and the mucus plug and desaturation persisted. Mepolizumab (100 mg/month) subcutaneously cleared the plug and improved BA. This case demonstrates that mepolizumab can treat patients with ABPM and refractory BA.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.